Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
2.480
+0.050 (2.06%)
At close: May 13, 2025, 4:00 PM
2.450
-0.030 (-1.21%)
Pre-market: May 14, 2025, 7:00 AM EDT

Akebia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
May '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Market Capitalization
651415234106395405
Upgrade
Market Cap Growth
30.90%77.46%120.08%-73.16%-2.30%-46.16%
Upgrade
Enterprise Value
734484301121363241
Upgrade
Last Close Price
2.481.901.240.582.262.80
Upgrade
PS Ratio
2.932.591.200.361.871.37
Upgrade
PB Ratio
26.40-8.43-7.6420.305.341.63
Upgrade
P/TBV Ratio
-----8.36
Upgrade
EV/Sales Ratio
3.973.021.550.411.710.82
Upgrade
EV/EBITDA Ratio
71.90--39.44--
Upgrade
Debt / Equity Ratio
7.96-3.84-4.7230.072.560.51
Upgrade
Debt / EBITDA Ratio
12.87--18.82--
Upgrade
Asset Turnover
0.690.690.650.660.360.42
Upgrade
Inventory Turnover
1.401.642.130.771.670.72
Upgrade
Quick Ratio
1.921.070.821.010.791.59
Upgrade
Current Ratio
2.231.411.181.431.041.99
Upgrade
Return on Equity (ROE)
----237.83%-175.37%-119.82%
Upgrade
Return on Assets (ROA)
-4.26%-12.49%-9.30%-4.89%-24.27%-15.41%
Upgrade
Return on Capital (ROIC)
-7.83%-22.81%-20.14%-10.17%-44.71%-24.88%
Upgrade
Earnings Yield
-6.96%-16.74%-22.23%-88.77%-71.32%-95.09%
Upgrade
FCF Yield
-5.35%-9.82%-10.01%-69.03%-63.99%-27.35%
Upgrade
Buyback Yield / Dilution
-13.54%-12.53%-2.56%-10.14%-19.85%-16.95%
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q